Locoregional radionuclide therapy of glioblastoma with [211At]At-PDA-FAPI

Abstract Glioblastoma is the most common and aggressive tumor of the central nervous system. Locoregional administration of therapeutic radiopharmaceuticals appears to be a promising modality for recurrent glioblastomas. In this study, fibroblast activation protein alpha (FAPα) targeting molecule fi...

Full description

Saved in:
Bibliographic Details
Main Authors: Huan Ma, Tianzhen Ye, Guofeng Qu, Yilin Qin, Jiali Liao, Yuanyou Yang, Wei Zhang, Ning Liu, Feize Li
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-03356-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849704460030312448
author Huan Ma
Tianzhen Ye
Guofeng Qu
Yilin Qin
Jiali Liao
Yuanyou Yang
Wei Zhang
Ning Liu
Feize Li
author_facet Huan Ma
Tianzhen Ye
Guofeng Qu
Yilin Qin
Jiali Liao
Yuanyou Yang
Wei Zhang
Ning Liu
Feize Li
author_sort Huan Ma
collection DOAJ
description Abstract Glioblastoma is the most common and aggressive tumor of the central nervous system. Locoregional administration of therapeutic radiopharmaceuticals appears to be a promising modality for recurrent glioblastomas. In this study, fibroblast activation protein alpha (FAPα) targeting molecule fibroblast activation protein inhibitor-04 (FAPI-04) was conjugated to polydopamine (PDA) nanoparticles, and then, α-emitter astatine-211 was labeled onto the nanocomposite to form [211At]At-PDA-FAPI. In vitro, [211At]At-PDA-FAPI was able to significantly reduce the cell viability, induce DSB formation, arrest cell cycle at G2/M phase and promote cell apoptosis. Furthermore, [211At]At-PDA-FAPI exhibited effective tumor inhibition ability in U87MG xenografts. Mice received 0.56 MBq [211At]At-PDA-FAPI showed a reduced tumor volume of approximately 65% on the 9th day after injection, and the median survival in this group (48 days) was obviously improved compared with that in the saline group (18 days). Meanwhile, increased apoptosis was also observed in tumor sites after [211At]At-PDA-FAPI treatment. In addition, H&E analysis of major organs confirmed the biological safety of [211At]At-PDA-FAPI. This study provides an effective and promising strategy for locoregional treatment of glioblastoma.
format Article
id doaj-art-a5a4fae4c9c24cf69bf3c2f7537726b0
institution DOAJ
issn 2045-2322
language English
publishDate 2025-05-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-a5a4fae4c9c24cf69bf3c2f7537726b02025-08-20T03:16:46ZengNature PortfolioScientific Reports2045-23222025-05-0115111210.1038/s41598-025-03356-2Locoregional radionuclide therapy of glioblastoma with [211At]At-PDA-FAPIHuan Ma0Tianzhen Ye1Guofeng Qu2Yilin Qin3Jiali Liao4Yuanyou Yang5Wei Zhang6Ning Liu7Feize Li8Department of Nuclear Medicine, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of ChinaKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan UniversityKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan UniversityKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan UniversityKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan UniversityKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan UniversityDepartment of Nuclear Medicine, Sichuan Provincial People’s Hospital, School of Medicine, University of Electronic Science and Technology of ChinaKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan UniversityKey Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan UniversityAbstract Glioblastoma is the most common and aggressive tumor of the central nervous system. Locoregional administration of therapeutic radiopharmaceuticals appears to be a promising modality for recurrent glioblastomas. In this study, fibroblast activation protein alpha (FAPα) targeting molecule fibroblast activation protein inhibitor-04 (FAPI-04) was conjugated to polydopamine (PDA) nanoparticles, and then, α-emitter astatine-211 was labeled onto the nanocomposite to form [211At]At-PDA-FAPI. In vitro, [211At]At-PDA-FAPI was able to significantly reduce the cell viability, induce DSB formation, arrest cell cycle at G2/M phase and promote cell apoptosis. Furthermore, [211At]At-PDA-FAPI exhibited effective tumor inhibition ability in U87MG xenografts. Mice received 0.56 MBq [211At]At-PDA-FAPI showed a reduced tumor volume of approximately 65% on the 9th day after injection, and the median survival in this group (48 days) was obviously improved compared with that in the saline group (18 days). Meanwhile, increased apoptosis was also observed in tumor sites after [211At]At-PDA-FAPI treatment. In addition, H&E analysis of major organs confirmed the biological safety of [211At]At-PDA-FAPI. This study provides an effective and promising strategy for locoregional treatment of glioblastoma.https://doi.org/10.1038/s41598-025-03356-2Astatine-211Targeted alpha therapyFibroblast activation protein inhibitorGlioblastomaPolydopamine
spellingShingle Huan Ma
Tianzhen Ye
Guofeng Qu
Yilin Qin
Jiali Liao
Yuanyou Yang
Wei Zhang
Ning Liu
Feize Li
Locoregional radionuclide therapy of glioblastoma with [211At]At-PDA-FAPI
Scientific Reports
Astatine-211
Targeted alpha therapy
Fibroblast activation protein inhibitor
Glioblastoma
Polydopamine
title Locoregional radionuclide therapy of glioblastoma with [211At]At-PDA-FAPI
title_full Locoregional radionuclide therapy of glioblastoma with [211At]At-PDA-FAPI
title_fullStr Locoregional radionuclide therapy of glioblastoma with [211At]At-PDA-FAPI
title_full_unstemmed Locoregional radionuclide therapy of glioblastoma with [211At]At-PDA-FAPI
title_short Locoregional radionuclide therapy of glioblastoma with [211At]At-PDA-FAPI
title_sort locoregional radionuclide therapy of glioblastoma with 211at at pda fapi
topic Astatine-211
Targeted alpha therapy
Fibroblast activation protein inhibitor
Glioblastoma
Polydopamine
url https://doi.org/10.1038/s41598-025-03356-2
work_keys_str_mv AT huanma locoregionalradionuclidetherapyofglioblastomawith211atatpdafapi
AT tianzhenye locoregionalradionuclidetherapyofglioblastomawith211atatpdafapi
AT guofengqu locoregionalradionuclidetherapyofglioblastomawith211atatpdafapi
AT yilinqin locoregionalradionuclidetherapyofglioblastomawith211atatpdafapi
AT jialiliao locoregionalradionuclidetherapyofglioblastomawith211atatpdafapi
AT yuanyouyang locoregionalradionuclidetherapyofglioblastomawith211atatpdafapi
AT weizhang locoregionalradionuclidetherapyofglioblastomawith211atatpdafapi
AT ningliu locoregionalradionuclidetherapyofglioblastomawith211atatpdafapi
AT feizeli locoregionalradionuclidetherapyofglioblastomawith211atatpdafapi